Patency of the ductus arteriosus in the premature infant: Is it pathologic? Should it be treated?

Current Opinion in Pediatrics

Volumn 16, Issue 2, 2004, Pages 146-151

  Laughon, Matthew M ^a   Simmons, Michael A ^a   Bose, Carl L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic lung disease; Ductus arteriosus; Indomethacin; Patent ductus arteriosus

Indexed keywords

IBUPROFEN; INDOMETACIN;

AORTA; ARTERY LIGATION; ARTERY STEAL SYNDROME; BLOOD FLOW VELOCITY; CARDIOPULMONARY HEMODYNAMICS; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DIASTOLE; DISEASE ASSOCIATION; DUCTUS ARTERIOSUS; ENTEROPATHY; HEART LEFT RIGHT SHUNT; HUMAN; INCIDENCE; LUNG CIRCULATION; LUNG COMPLIANCE; LUNG DISEASE; LUNG FLUID; LUNG MECHANICS; LUNG VOLUME; META ANALYSIS; MORBIDITY; NECROTIZING ENTEROCOLITIS; NONHUMAN; ORGAN BLOOD FLOW; PATENT DUCTUS ARTERIOSUS; PHYSICAL EXAMINATION; PHYSIOLOGY; PREMATURITY; PRIORITY JOURNAL; PULMONARY ARTERY; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHUNTING; SURGICAL TECHNIQUE; SYSTEMIC CIRCULATION; SYSTOLIC HEART MURMUR; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

DUCTUS ARTERIOSUS, PATENT; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES;

EID: 1642403036     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200404000-00005     Document Type: Review

References (30)

1. Rudolph AM: Distribution and regulation of blood flow in the fetal and neonatal lamb. Circ Res 1985, 57:811-821.
2. Dawes GS: Foetal and Neonatal Physiology. Chicago: Year Book Medical Publishers; 1969:91-103.
3. Levin DL, Mills LJ, Weinberg AG: Hemodynamic, pulmonary vascular, and myocardial abnormalities secondary to pharmacologic constriction of the fetal ductus arteriosus. A possible mechanism for persistent pulmonary hypertension and transient tricuspid insufficiency in the newborn infant. Circulation 1979, 60:360-364.
4. Van Marter LJ, Leviton A, Allred EN, et al.: Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics 1996, 97:658-663.
5. Teitel DF, Iwamoto HS, Rudolph AM: Effects of birth-related events on central blood flow patterns. Pediatr Res 1987, 22:557-566.
6. Gentile R, Stevenson G, Dooley T, et al.: Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. J Pediatr 1981, 98:443-448.
7. Clyman RI, Waleh N, Black SM, et al.: Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension, and vasa vasorum. Pediatr Res 1998, 43:633-644.
8. Clyman R: Developmental physiology of the ductus arteriosus. In Fetal and Neonatal Cardiology. Edited by Long W. Philadelphia: WB Saunders; 1990:64-75.
9. Clyman R, Narayanan M: Patent ductus arteriosus: a physiologic basis for current treatment practices. In Current Topics in Neonatology. Philadelphia: WB Saunders; 2000:71-91.
10. Urquhart DS, Nicholl RM: How good is clinical examination at detecting a significant patent ductus arteriosus in the preterm neonate? Arch Dis Child 2003, 88:85-86. A systematic review to determine the sensitivity and specificity of the physical examination to detect a PDA.
11. Davis P, Turner-Gomes S, Cunningham K, et al.: Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med 1995, 149:1136-1141.
12. Teitel DF: Circulatory adjustments to postnatal life. Semin Perinatol 1988, 12:96-103.
13. Morrow WR, Taylor AF, Kinsella JP, et al.: Effect of ductal patency on organ blood flow and pulmonary function in the preterm baboon with hyaline membrane disease. Crit Care Med 1995, 23:179-186.
14. Alpan G, Scheerer R, Bland R, et al.: Patent ductus arteriosus increases lung fluid filtration in preterm lambs. Pediatr Res 1991, 30:616-621.
15. Rojas MA, Gonzalez A, Bancalari E, et al.: Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995, 126:605-610.
16. Marshall DD, Kotelchuck M, Young TE, et al.: Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999, 104:1345-1350.
17. Shimada S, Kasai T, Hoshi A, et al.: Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int 2003, 45:255-262. The investigators used echocardiography to document renal and splanchnic decreased blood flow velocities despite increased left ventricular output in infants with a hemodynamically significant PDA.
18. Meyers RL, Alpan G, Lin E, et al.: Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res 1991, 29:569-574.
19. Guthrie SO, Gordon PV, Thomas V, et al.: Necrotizing enterocolitis among neonates in the United States. J Perinatol 2003, 23:278-285.
20. Cotton RB, Stahlman MT, Bender HW, et al.: Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr 1978, 93:647-651.
21. Merritt TA, DiSessa TG, Feldman BH, et al.: Closure of the patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr 1978, 93:639-646.
22. Nestrud RM, Hill DE, Arlington RW, et al.: Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Dev Pharmacol Ther 1980, 1:125-136.
23. Yanagi RM, Wilson A, Newfeld EA, et al.: Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics 1981, 67:647-652.
24. Yeh TF, Luken JA, Thalji A, et al.: Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus-a double-blind controlled study. J Pediatr 1981, 98:137-145.
25. Fowlie PW, Davis PG: Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002(3):CD000174. This study is a metaanalysis that includes 19 trials and 2872 patients, and the results suggest that, despite a decrease in some short-term morbidities (decreased incidences of PDA and intraventricular hemorrhage (IVH)), there is no long-term benefit of prophylactic therapy.
26. Cooke L, Steer P, Woodgate P: Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2003(2):CD003745. This study is a metaanalysis that includes three trials and 97 patients, and the results suggest a small but significant decrease in duration of oxygen therapy with indomethacin.
27. Knight DB: The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001, 6:63-73.
28. Schmidt B, Davis P, Moddemann D, et al.: Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001, 344:1966-1972.
29. Ohlsson A, Walia R, Shah S: Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2003:CD003481. This metaanalysis demonstrates that ibuprofen and indomethacin are effective in closing the PDA but that ibuprofen therapy is associated with an increased incidence of CLD.
30. Koehne PS, Bein G, Alexi-Meskhishvili V, et al.: Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med 2001, 29:327-334.